恶性胸膜间皮瘤的分子基础。
The Molecular Basis of Malignant Pleural Mesothelioma.
机构信息
Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
出版信息
Thorac Surg Clin. 2020 Nov;30(4):383-393. doi: 10.1016/j.thorsurg.2020.08.005. Epub 2020 Sep 12.
Abstract
Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy of the pleural lining associated with asbestos exposure in greater than 80% of cases. It is characterized by molecular heterogeneity both between patients and within individual tumors. Next-generation sequencing technology and novel computational techniques have resulted in a greater understanding of the epigenetic, genetic, and transcriptomic hallmarks of MPM. This article reviews these features and discusses the implications of advances in MPM molecular biology in clinical practice.
摘要
恶性胸膜间皮瘤（MPM）是一种罕见的、侵袭性的胸膜衬里恶性肿瘤，与 80%以上病例中的石棉暴露有关。它的特点是患者之间和单个肿瘤内的分子异质性。下一代测序技术和新型计算技术使人们对 MPM 的表观遗传、遗传和转录组特征有了更深入的了解。本文综述了这些特征，并讨论了 MPM 分子生物学进展在临床实践中的意义。
相似文献
1
The Molecular Basis of Malignant Pleural Mesothelioma.恶性胸膜间皮瘤的分子基础。
Thorac Surg Clin. 2020 Nov;30(4):383-393. doi: 10.1016/j.thorsurg.2020.08.005. Epub 2020 Sep 12.
2
[Molecular heterogeneity of malignant pleural mesotheliomas].[恶性胸膜间皮瘤的分子异质性]
Bull Cancer. 2018 Jan;105(1):35-45. doi: 10.1016/j.bulcan.2017.11.007. Epub 2017 Dec 23.
3
Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma.多部位肿瘤取样突出了恶性胸膜间皮瘤的肿瘤内分子异质性。
Genome Med. 2021 Jul 14;13(1):113. doi: 10.1186/s13073-021-00931-w.
4
Genomics and Functional Genomics of Malignant Pleural Mesothelioma.恶性胸膜间皮瘤的基因组学和功能基因组学。
Int J Mol Sci. 2020 Sep 1;21(17):6342. doi: 10.3390/ijms21176342.
5
Does Simian Virus 40 (SV40) Have a Role in UK Malignant Pleural Mesothelioma? No Role is Identified in a Sensitive RNA In Situ Hybridization Study on Potentially Affected Birth Cohorts.猴病毒 40（SV40）是否在英国恶性胸膜间皮瘤中起作用？在对可能受影响的出生队列进行的敏感 RNA 原位杂交研究中，未发现作用。
Appl Immunohistochem Mol Morphol. 2020 Jul;28(6):444-447. doi: 10.1097/PAI.0000000000000779.
6
Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.恶性胸膜间皮瘤和间皮增生：一种用于鉴别诊断的新分子工具。
Oncotarget. 2017 Jan 10;8(2):2758-2770. doi: 10.18632/oncotarget.13174.
7
Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.外周血 DNA 甲基化作为石棉暴露人群恶性胸膜间皮瘤的潜在生物标志物。
J Thorac Oncol. 2019 Mar;14(3):527-539. doi: 10.1016/j.jtho.2018.10.163. Epub 2018 Nov 5.
8
Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival.恶性胸膜间皮瘤的遗传改变：与肿瘤异质性和总生存的关系。
Mol Oncol. 2020 Jun;14(6):1207-1223. doi: 10.1002/1878-0261.12651. Epub 2020 Mar 10.
9
Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas.肺部和胸腔病理学的挑战：胸膜间皮瘤分类的分子进展。
Virchows Arch. 2021 Jan;478(1):73-80. doi: 10.1007/s00428-020-02980-9. Epub 2021 Jan 7.
10
Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden.丹麦、芬兰、挪威和瑞典间皮瘤发病、死亡和生存情况在石棉使用前后的变化。
BMC Cancer. 2021 Nov 8;21(1):1189. doi: 10.1186/s12885-021-08913-2.
引用本文的文献
1
Molecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities.胸膜间皮瘤的分子见解：揭示致病机制与治疗机遇
Diagnostics (Basel). 2025 May 24;15(11):1323. doi: 10.3390/diagnostics15111323.
2
Exploration of the anticancer properties of Caffeic Acid in malignant mesothelioma cells.咖啡酸在恶性间皮瘤细胞中的抗癌特性研究。
Med Oncol. 2025 Jun 10;42(7):249. doi: 10.1007/s12032-025-02802-5.
3
Transcriptional landscape of pleural mesothelioma patients in relation to NF2 gene mutational status.与NF2基因突变状态相关的胸膜间皮瘤患者的转录图谱。
J Egypt Natl Canc Inst. 2025 Jun 9;37(1):25. doi: 10.1186/s43046-025-00284-0.
4
Integrative eQTL and Mendelian randomization analysis reveals key genetic markers in mesothelioma.整合性表达数量性状基因座（eQTL）与孟德尔随机化分析揭示了间皮瘤中的关键遗传标记。
Respir Res. 2025 Apr 13;26(1):140. doi: 10.1186/s12931-025-03219-4.
5
Prognostic Value of PD-L1, BAP-1 and ILK in Pleural Mesothelioma.PD-L1、BAP-1和整合素连接激酶在胸膜间皮瘤中的预后价值
J Clin Med. 2024 Dec 2;13(23):7322. doi: 10.3390/jcm13237322.
6
Clinical Perspectives and Novel Preclinical Models of Malignant Pleural Mesothelioma: A Critical Review.恶性胸膜间皮瘤的临床观点与新型临床前模型：一项批判性综述
ACS Pharmacol Transl Sci. 2024 Oct 14;7(11):3299-3333. doi: 10.1021/acsptsci.4c00324. eCollection 2024 Nov 8.
7
Case report: targeted therapy of malignant pleural mesothelioma with anaplastic lymphoma kinase receptor tyrosine kinase gene fusion mutation by crizotinib.病例报告：克唑替尼治疗间变性淋巴瘤激酶受体酪氨酸激酶基因融合突变的恶性胸膜间皮瘤。
J Int Med Res. 2024 Nov;52(11):3000605241287320. doi: 10.1177/03000605241287320.
8
Capsaicin Exerts Antitumor Activity in Mesothelioma Cells.辣椒素对间皮瘤细胞具有抗肿瘤活性。
Nutrients. 2024 Nov 1;16(21):3758. doi: 10.3390/nu16213758.
9
A Case of Malignant Pleural Mesothelioma With Unknown Asbestos Exposure.一例石棉暴露史不明的恶性胸膜间皮瘤病例
Cureus. 2024 Sep 23;16(9):e69966. doi: 10.7759/cureus.69966. eCollection 2024 Sep.
10
Volatile organic compound analysis of malignant pleural mesothelioma chorioallantoic membrane xenografts.恶性胸膜间皮瘤绒毛尿囊膜异种移植物的挥发性有机化合物分析。
J Breath Res. 2024 Sep 11;18(4):046010. doi: 10.1088/1752-7163/ad7166.
本文引用的文献
1
Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future.调控微小RNA用于治疗恶性胸膜间皮瘤：过去、现在与未来
Front Oncol. 2020 Feb 7;10:105. doi: 10.3389/fonc.2020.00105. eCollection 2020.
2
Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.恶性胸膜间皮瘤患者中 DNA 损伤修复相关种系新突变。
J Thorac Oncol. 2020 Apr;15(4):655-660. doi: 10.1016/j.jtho.2019.12.111. Epub 2019 Dec 28.
3
Epigenetic Regulation of miRNA Expression in Malignant Mesothelioma: miRNAs as Biomarkers of Early Diagnosis and Therapy.恶性间皮瘤中miRNA表达的表观遗传调控：miRNA作为早期诊断和治疗的生物标志物
Front Oncol. 2019 Nov 29;9:1293. doi: 10.3389/fonc.2019.01293. eCollection 2019.
4
Pleural mesothelioma and lung cancer: the role of asbestos exposure and genetic variants in selected iron metabolism and inflammation genes.胸膜间皮瘤和肺癌：石棉暴露和选定铁代谢和炎症基因遗传变异的作用。
J Toxicol Environ Health A. 2019;82(20):1088-1102. doi: 10.1080/15287394.2019.1694612. Epub 2019 Nov 22.
5
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.自身免疫、检查点抑制剂治疗和免疫相关不良事件：综述。
Semin Cancer Biol. 2020 Aug;64:93-101. doi: 10.1016/j.semcancer.2019.06.012. Epub 2019 Jul 19.
6
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.间皮瘤：预防、诊断和治疗的科学线索。
CA Cancer J Clin. 2019 Sep;69(5):402-429. doi: 10.3322/caac.21572. Epub 2019 Jul 8.
7
The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.《应用于恶性胸膜间皮瘤治疗的放射治疗：美国国家癌症研究所胸部恶性肿瘤指导委员会、国际肺癌研究协会以及间皮瘤应用研究基金会的专家意见》。
J Thorac Oncol. 2019 Jul;14(7):1172-1183. doi: 10.1016/j.jtho.2019.03.030. Epub 2019 May 22.
8
The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment.凋亡缺陷在恶性间皮瘤发病机制中的作用及其对预后和治疗的影响。
Cancer Chemother Pharmacol. 2019 Aug;84(2):241-253. doi: 10.1007/s00280-019-03878-3. Epub 2019 May 22.
9
Quantitative relationships of exposure to chrysotile asbestos and mesothelioma mortality.接触温石棉与间皮瘤死亡率的定量关系。
Am J Ind Med. 2019 Jun;62(6):471-477. doi: 10.1002/ajim.22985. Epub 2019 May 13.
10
Immune checkpoint inhibition for the treatment of mesothelioma.免疫检查点抑制治疗间皮瘤。
Expert Opin Biol Ther. 2019 Jul;19(7):697-706. doi: 10.1080/14712598.2019.1606209. Epub 2019 May 2.
Zotero 插件